Literature DB >> 29128868

Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records.

Hao Yu Chen1,2, Line Dufresne2, Hannah Burr2, Athithan Ambikkumar2, Niko Yasui2, Kevin Luk2, Dilrini K Ranatunga3, Rachel A Whitmer3, Mark Lathrop4,5, James C Engert1,2,4, George Thanassoulis1,2.   

Abstract

Importance: Elevated lipoprotein(a) levels are a risk factor for aortic stenosis (AS). However, a large-scale replication of associations between LPA variants and AS, their interactions with risk factors, and the effect of multiple risk alleles is not well established. Objective: To replicate the association between LPA variants with AS and identify subgroups who are at higher risk of developing AS. Design, Setting, and Participants: This case-control study of AS included 44 703 individuals (3469 cases) 55 years or older who were enrolled in the Genetic Epidemiology Research on Aging cohort and who were members of the Kaiser Permanente Northern California health care delivery system. The study leveraged the linkage of administrative health data, electronic medical records, genotypes, and self-reported questionnaire data. The 3469 AS cases were diagnosed between January 1996 and December 2015. Individuals with congential valvular heart disease were excluded. Exposures: Two single-nucleotide polymorphisms in the LPA locus, rs10455872 and rs3798220, that are known to associate with circulating plasma lipoprotein(a) levels and an LPA risk score. Main Outcomes and Measures: Aortic stenosis or aortic valve replacement.
Results: The 44 703 participants were of European ancestry,of whom 22 019 (49.3%) were men. The mean (SD) age for the control group was 69.3 (8.3) years and the mean (SD) age for AS cases was 74.6 (8.5) years. Both LPA variants were associated with AS, with a per risk allele odds ratio of 1.34 (95% CI, 1.23-1.47; P = 1.7 × 10-10) for rs10455872 and 1.31 (95% CI, 1.09-1.58; P = 3.6 × 10-3) for rs3798220 after adjusting for age, age2, and sex. The results remained significant after adjusting for risk factors. The estimates were similar for an LPA risk score. Individuals with 2 risk alleles had a 2-fold or greater odds of AS compared with individuals with no risk alleles (for rs10455872, homozygous odds ratio, 2.05; 95% CI, 1.37-3.07; P = 5.3 × 10-4; for rs3798220, homozygous odds ratio, 3.74; 95% CI, 1.03-13.62; P = .05; and for compound heterygotes, odds ratio, 2.00; 95% CI, 1.17-3.44; P = .01). For rs10455872, the odds ratio for AS was greatest in individuals aged 55 to 64 years and declined with age (interaction P = .03). Each rs10455872 risk allele was also associated with AS that was diagnosed 0.71 years earlier (95% CI, -1.42 to 0; P = .05). Conclusions and Relevance: We provide a large-scale confirmation of the association between 2 LPA variants and AS, reaching genome-wide significance. In addition, individuals with 2 risk alleles have 2-fold or greater odds of developing AS. Age may modify these associations and identify subgroups who are at greater risk of developing AS.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29128868      PMCID: PMC5833523          DOI: 10.1001/jamacardio.2017.4266

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  22 in total

1.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.

Authors:  Pia R Kamstrup; Anne Tybjærg-Hansen; Børge G Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

Review 2.  Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.

Authors:  Evan A Stein; Frederick Raal
Journal:  Cardiovasc Drugs Ther       Date:  2016-02       Impact factor: 3.727

3.  Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels.

Authors:  Wensheng Lu; Yu-Ching Cheng; Keping Chen; Hong Wang; Glenn S Gerhard; Christopher D Still; Xin Chu; Rongze Yang; Ankita Parihar; Jeffrey R O'Connell; Toni I Pollin; Eduardo Angles-Cano; Michael J Quon; Braxton D Mitchell; Alan R Shuldiner; Mao Fu
Journal:  Hum Mol Genet       Date:  2015-01-09       Impact factor: 6.150

4.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

5.  A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data.

Authors:  Benjamin J Cairns; Sean Coffey; Ruth C Travis; Bernard Prendergast; Jane Green; James C Engert; Mark Lathrop; George Thanassoulis; Robert Clarke
Journal:  Circulation       Date:  2017-03-21       Impact factor: 29.690

6.  Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.

Authors:  Connor A Emdin; Amit V Khera; Pradeep Natarajan; Derek Klarin; Hong-Hee Won; Gina M Peloso; Nathan O Stitziel; Akihiro Nomura; Seyedeh M Zekavat; Alexander G Bick; Namrata Gupta; Rosanna Asselta; Stefano Duga; Piera Angelica Merlini; Adolfo Correa; Thorsten Kessler; James G Wilson; Matthew J Bown; Alistair S Hall; Peter S Braund; Nilesh J Samani; Heribert Schunkert; Jaume Marrugat; Roberto Elosua; Ruth McPherson; Martin Farrall; Hugh Watkins; Cristen Willer; Gonçalo R Abecasis; Janine F Felix; Ramachandran S Vasan; Eric Lander; Daniel J Rader; John Danesh; Diego Ardissino; Stacey Gabriel; Danish Saleheen; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

7.  Genotype imputation with thousands of genomes.

Authors:  Bryan Howie; Jonathan Marchini; Matthew Stephens
Journal:  G3 (Bethesda)       Date:  2011-11-01       Impact factor: 3.154

8.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

9.  Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; Marie-Pierre Dubé; Eric Rhéaume; Nicholas J Wareham; Kay-Tee Khaw; Manjinder S Sandhu; Jean-Claude Tardif
Journal:  Circ Cardiovasc Genet       Date:  2014-04-05

10.  Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.

Authors:  J C Hopewell; U Seedorf; M Farrall; S Parish; T Kyriakou; A Goel; A Hamsten; R Collins; H Watkins; R Clarke
Journal:  J Intern Med       Date:  2014-02-05       Impact factor: 8.989

View more
  15 in total

1.  Errors in Data Presentation, Funding, and Acknowledgments.

Authors: 
Journal:  JAMA Cardiol       Date:  2018-10-01       Impact factor: 14.676

2.  Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification.

Authors:  Nicolas Perrot; Sébastien Thériault; Christian Dina; Hao Yu Chen; S Matthijs Boekholdt; Sidwell Rigade; Audrey-Anne Després; Anthony Poulin; Romain Capoulade; Thierry Le Tourneau; David Messika-Zeitoun; Mikaël Trottier; Michel Tessier; Jean Guimond; Maxime Nadeau; James C Engert; Kay-Tee Khaw; Nicholas J Wareham; Marc R Dweck; Patrick Mathieu; Philippe Pibarot; Jean-Jacques Schott; George Thanassoulis; Marie-Annick Clavel; Yohan Bossé; Benoit J Arsenault
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

3.  Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.

Authors:  Romain Capoulade; Calvin Yeang; Kwan L Chan; Philippe Pibarot; Sotirios Tsimikas
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

Review 4.  Risk factors for valvular calcification.

Authors:  Hao Yu Chen; James C Engert; George Thanassoulis
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-04       Impact factor: 3.243

Review 5.  Calcific Aortic Valve Stenosis and Atherosclerotic Calcification.

Authors:  Michel Pompeu Barros de Oliveira Sá; Luiz Rafael P Cavalcanti; Álvaro M Perazzo; Rafael A F Gomes; Marie-Annick Clavel; Philippe Pibarot; Giuseppe Biondi-Zoccai; Konstantin Zhigalov; Alexander Weymann; Arjang Ruhparwar; Ricardo Carvalho Lima
Journal:  Curr Atheroscler Rep       Date:  2020-01-07       Impact factor: 5.113

6.  Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

Authors:  Teresa Trenkwalder; Christopher P Nelson; Muntaser D Musameh; Ify R Mordi; Thorsten Kessler; Costanza Pellegrini; Radoslaw Debiec; Tobias Rheude; Viktor Lazovic; Lingyao Zeng; Andreas Martinsson; J Gustav Smith; Jesper R Gådin; Anders Franco-Cereceda; Per Eriksson; Jonas B Nielsen; Sarah E Graham; Cristen J Willer; Kristian Hveem; Adnan Kastrati; Peter S Braund; Colin N A Palmer; Amparo Aracil; Oliver Husser; Wolfgang Koenig; Heribert Schunkert; Chim C Lang; Christian Hengstenberg; Nilesh J Samani
Journal:  Int J Cardiol       Date:  2018-11-17       Impact factor: 4.164

Review 7.  Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Authors:  Sotirios Tsimikas
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

8.  Lipoprotein(a).

Authors:  Florian Kronenberg
Journal:  Handb Exp Pharmacol       Date:  2022

Review 9.  Degenerative Aortic Stenosis, Dyslipidemia and Possibilities of Medical Treatment.

Authors:  Rita Kleinauskienė; Regina Jonkaitienė
Journal:  Medicina (Kaunas)       Date:  2018-04-25       Impact factor: 2.430

10.  Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography.

Authors:  Audrey-Anne Després; Nicolas Perrot; Anthony Poulin; Lionel Tastet; Mylène Shen; Hao Yu Chen; Raphaëlle Bourgeois; Mikaël Trottier; Michel Tessier; Jean Guimond; Maxime Nadeau; James C Engert; Sébastien Thériault; Yohan Bossé; Joseph L Witztum; Patrick Couture; Patrick Mathieu; Marc R Dweck; Sotirios Tsimikas; George Thanassoulis; Philippe Pibarot; Marie-Annick Clavel; Benoit J Arsenault
Journal:  CJC Open       Date:  2019-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.